Amyris Inc  

(Public, NASDAQ:AMRS)   Watch this stock  
Find more results for AMRS
2.66
-0.04 (-1.48%)
Jun 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.65 - 2.77
52 week 2.16 - 4.56
Open 2.71
Vol / Avg. 82,470.00/215,310.00
Mkt cap 182.77M
P/E     -
Div/yield     -
EPS -2.33
Shares 68.71M
Beta     -
Inst. own 57%
Jul 29, 2013
Q2 2013 Amyris Inc Earnings Release Add to calendar
May 30, 2013
Amyris Inc at Cowen Technology, Media & Telecom Conference
May 13, 2013
Amyris Inc at Deutsche Bank dbAccess Clean Tech, Utilities and Power One-on-One Conference
May 9, 2013
Amyris Inc Annual Shareholder Meeting
May 6, 2013
Q1 2013 Amyris Inc Earnings Release
Apr 30, 2013
Q1 2013 Amyris Inc Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -410.66% -279.58%
Operating margin -402.49% -273.86%
EBITD margin - -191.87%
Return on average assets -53.57% -73.20%
Return on average equity -206.87% -179.82%
Employees 380 -
Carbon Disclosure Rating - -

Address

Ste. 100, 5885 Hollis Street
EMERYVILLE, CA 94608
United States - Map
+1-510-4500761 (Phone)
+1-510-2252645 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Amyris, Inc., formerly Amyris Biotechnologies, Inc. develops and provides renewable compounds for a variety of markets. As of December 31, 2012, the Company built and applied its industrial synthetic biology platform to provide alternatives to petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. The Company is focused on developing a range of products to address six markets: cosmetics, lubricants, flavors and fragrances, polymers, consumer products and transportation fuels. The Company�s call these No Compromise products because it design them to perform comparably to, or better than, available products. It genetically modifies micro organisms, primarily yeast, and uses them as living factories in established fermentation processes to convert plant-sourced sugars into thousands of molecules. The Company has two operating subsidiaries, Amyris Brasil Ltda. (formerly Amyris Brasil S.A.), or Amyris Brasil, and Amyris Fuels LLC, or Amyris Fuels.

Officers and directors

John G Melo President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Steven R. Mills Chief Financial Officer, Principal Accounting Officer
Bio & Compensation  - Reuters
Joel Cherry Ph.D. President - Research and Development
Bio & Compensation  - Reuters
Paulo Diniz President of Amyris Brasil Ltda.
Bio & Compensation  - Reuters
Karen D. Rohde Chief Human Resources Officer
Bio & Compensation  - Reuters
Christine Ring Ph.D. Senior Vice President, Chief Intellectual Property Counsel
Bio & Compensation  - Reuters
Joel Velasco Senior Vice President
Bio & Compensation  - Reuters
Jack D Newman Ph.D. Chief Science Officer
Bio & Compensation  - Reuters
Gary Loeb Vice President, General Counsel, Corporate Secretary
Bio & Compensation  - Reuters
Charles Kraft Vice President, Global Manufacturing & Process Development
Bio & Compensation  - Reuters